Registrant : Organisation or self-employed individual
| Name/company name: |
Novartis International AG |
| Acronym: |
|
| Legal status: |
Corporation
|
| Website address: |
http://www.novartis.com
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
Joseph Jimenez
|
| Position: |
Chief Executive Officer |
Permanent person in charge of EU relations
| Surname, Name: |
Mr
Andras Fehervary
|
| Position: |
Head of Government & Public Affairs Europe |
Contact details:
| Contact details of organisation's head office: |
1 Novartis International AG Forum 1
Basel CH-4002
SWITZERLAND
|
| Telephone number: |
(+41) 61 324 11 11 |
| Fax number: |
(+) |
| Other contact information: |
Novartis European Public Affairs
Rue du Trone, 108
B-1050 Brussels
Belgium
Tel: +32 2 246 1975
|
Goals / remit
| Goals / remit of the organisation: |
Our mission is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in generics, eyecare, vaccines and consumer health products.
In 2008, Novartis invested USD 7.2 billion in R&D activities. This is one of the highest figures in the industry relative to net sales (17.4%).
With approximately 130 000 associates in 140 countries worldwide, Novartis associates share a vision of a better today and tomorrow for patients.
Novartis puts patients first. We want to create value for all patients, including those who cannot afford treatment.
During 2008, medicines and vaccines from Novartis treated and protected more than (estimated) 850 million people around the world. Novartis contributed treatments worth USD 1.26 billion through access-to-medicine programs, reaching 74 million patients in need.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
6
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
| First name
|
Surname
|
Start Date |
End Date |
|
Elisaveta
|
Voynova
|
26/02/13
|
21/06/13
|
|
Maximilian Alexander
|
GÖTZ VON OLENHUSEN
|
06/02/13
|
04/02/14
|
|
Joaquin
|
de Santos
|
12/04/13
|
10/04/14
|
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
At European level, Novartis is committed to working in partnership with the institutions of the European Union to support policies and actions that improve healthcare and foster the competitiveness of European Industry.
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Competition
- Consumer Affairs
- Customs
- Development
- Economic and Financial Affairs
- Employment and Social Affairs
- Enlargement
- Enterprise
- Environment
- External Relations
- Food Safety
- General and Institutional Affairs
- Home Affairs
- Information Society
- Internal Market
- Justice and Fundamental Rights
- Public Health
- Regional Policy
- Research and Technology
- Taxation
- Trade
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
Member of EFPIA, EBE, EVM, EuropaBio, EGA, AESGP, EUROMCONTACT, CEFIC, BusinessEurope (Economiesuisse), EDMA, Eucomed, BritCham.
|
Financial data
| Financial year: |
01/2012
-
12/2012
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
600000
€ - 700000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
The estimated costs are calculated based on the proportion of working time spent by Novartis associates on representing interests to the EU institutions in 2012. This proportion is applied to the overall personnel and overhead costs.
|
|
